Skip to main content
TipRanks
Go Ultimate75% OFF

Xeris Pharmaceuticals (XERS) Stock Price & Analysis

1,122 Followers

XERS Stock Chart & Stats

$16.70$0.04(0.24%)
At close: 4:00 PM EST
$7.5$10$12.5$15Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$16.54 - $16.98
52-Week Range
$5.25 - $16.98
Previous Close
$16.66
Volume
N/A
Average Volume (3M)
3.05M
Market Cap
$3.05B
Enterprise Value
$1.91B
Total Cash (Recent Filing)
$131.08M
Total Debt (Recent Filing)
$226.07M
Price to Earnings (P/E)
―
Beta
0.82
Next Earnings
Mar 10, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth And Commercial Momentum

Strong growth across the commercial portfolio is expanding Xeris’s revenue base and supports operating leverage as the business scales. Raised full-year guidance indicates management sees momentum continuing beyond a single quarter, strengthening the company’s medium-term growth profile.

Cash Generation And Gross Margins

High gross margins combined with strong operating and free cash flow demonstrate that Xeris’s approved-product model is producing meaningful cash while revenue grows. This financial productivity can support commercial investment, pipeline development, and greater self-funding capacity over the next several quarters.

Protected Pipeline And Intellectual Property

Strengthened patent protection gives XP-8121 a potentially durable period of market exclusivity if development succeeds. Advancing toward a pivotal study also creates a credible longer-term growth option that could broaden Xeris’s portfolio and leverage its existing commercial infrastructure.

Bears Say

Elevated Balance Sheet Leverage

High leverage remains a material constraint on financial flexibility despite improving equity and cash generation. Debt relative to the equity base could limit investment choices, increase sensitivity to any slowdown in growth, and make it harder to absorb weaker profitability or unexpected execution demands.

GAAP Profitability Is Not Yet Durable

Xeris has improved operating profitability, but the continuing TTM net loss shows that bottom-line earnings have not yet become consistently positive. Until this converts into durable net income, shareholder returns remain less predictable and the company remains more dependent on execution and cash-flow strength.

Reimbursement And Access Friction

Ongoing prior authorization requirements can slow patient starts and add work for clinicians, patients, and Xeris’s support organization. Because management does not expect the issue to change immediately, access friction may continue limiting Recorlev conversion and raise the commercial resources needed to sustain growth.

Xeris Pharmaceuticals News

XERS FAQ

What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest stock price was $5.25 and its highest was $16.98 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $3.05B.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s next earnings report is estimated for Mar 10, 2027 (not yet confirmed), which is in 113 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Nov 05, 2026. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.032 by $0.028.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is 0.07.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 182,700,040 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of $0.06 in its last earnings report, beating expectations of $0.032. Following the earnings report the stock price went up 25.048%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Hedge funds hold Xeris Pharmaceuticals shares: the largest hedge-fund position in Xeris Pharmaceuticals is 72,326,894 shares, and hedge funds increased their holdings by 1.6M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology